NCT02724436

Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma

Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma: A Randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Eastern Hepatobiliary Surgery Hospital · Academic / Other
• Sex: All
• Age: 17 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC. The 5-year overall survival (OS) rates after hepatic resection were range from 25% to 45%. Transarterial chemoembolization (TACE) is the major treatment option for the unresectable primary or secondary liver malignancies. Yittrium-90 (Y-90) is a pure beta-emitter, without any toxic effect or immune rejection. There are ample data that support the use of Y-90 microspheres for primary and metastatic liver tumors. The aim of our study was to compare the clinical outcome of radioembolization with Y-90 and TACE and provide a new strategy for the treatment of intermediate and advanced hepatocellular carcinoma with portal vein thrombus by conduting a randomized trial.

Conditions

• Hepatocellular Carcinoma
• Radioembolization

Interventions

Type	Name	Description
PROCEDURE	TACE
PROCEDURE	radioembolization with Y-90	radioembolization with Y-90

Timeline

• Start date: 2012-12-01
• Primary completion: 2014-12-01
• Completion: 2015-12-01
• First posted: 2016-03-31
• Last updated: 2016-03-31

Locations

1 site across 1 country: China